Research
Hormonal
Liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) are FDA-approved GLP-1 receptor agonists for weight management.
Practitioners can consider liraglutide and semaglutide as viable options for patients needing weight management.
StrongSupportsmedium confidence
Two injectable incretin-based glucagon-like peptide-1 (GLP-1) receptor agonists — liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) — have been approved by the Food and Drug Administration (FDA) for weight management.
Why this rating
The claim is based on FDA approval, indicating a high level of evidence.
Source
Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists?
E. Dale Abel · New England Journal of Medicine · 2023
reviewCited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →